Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mauna Kea Technologies (XPAR:ALMKT) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Mauna Kea Technologies's Liquidation Value for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mauna Kea Technologies Total Current Assets Related Terms
Mauna Kea Technologies Total Current Assets Historical Data
* Premium members only.
The historical data trend for Mauna Kea Technologies's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of €11.02 Mil mean?
Mauna Kea Technologies (XPAR:ALMKT) has a Total Current Assets of €11.02 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Mauna Kea Technologies and its competitors.
Is Mauna Kea Technologies' Total Current Assets too high?
Mauna Kea Technologies' current Total Current Assets is €11.02 Mil. Overall, Mauna Kea Technologies has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' Total Current Assets compare to ABT and SYK?
Mauna Kea Technologies' Total Current Assets of €11.02 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Devices & Instruments company?
A good Total Current Assets depends on the Medical Devices & Instruments industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Mauna Kea Technologies and its competitors. Mauna Kea Technologies's current Total Current Assets is €11.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (XPAR:ALMKT) is currently considered Fairly Valued. The stock's GF Value™ is €0.14, compared to a current price of €0.15 — trading 10% above its estimated fair value. The current Total Current Assets is €11.02 Mil. Mauna Kea Technologies' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Mauna Kea Technologies (XPAR:ALMKT), the current Total Current Assets is €11.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (XPAR:ALMKT) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.15 is trading 10% above its estimated GF Value™ of €0.14.
GuruFocus considers Mauna Kea Technologies to be Fairly Valued.
Key valuation signals for XPAR:ALMKT:
Total Current Assets: €11.02 Mil
GF Value™: €0.14 vs. price of €0.15 (10% above fair value)
No single metric tells the full story. See the XPAR:ALMKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
39GF Score
Get the complete analysis for XPAR:ALMKT
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALMKT has been successfully added to your 
